On 22 May 2023, EASL convened a ground-breaking event on the sidelines of the 76th World Health Assembly (WHA76) in partnership with national and regional liver associations, sister organisations in obesity, diabetes, and heart disease, and patient advocates. The event marked the first formal engagement of WHO in discussions on MASLD and provided an important milestone in the long process of fully integrating MASLD in WHO’s NCD portfolio. Consistent engagement and advocacy with the World Health Organization is critical in advancing the global agenda on MASLD. Therefore, on 31st January 2024, directly following the 154th WHO Executive Board meeting (EB154), EASL will convene a multi-stakeholder discussion to raise the profile of liver diseases on the global stage. Under the theme: “Steatotic liver disease – the missing piece in the NCD puzzle”, EASL collaborates with representatives from the WHO, patient advocate, NCD Alliance, and more to discuss priorities and recommendations for the upcoming WHA77 agenda. This high level discussion calls on Member States to recognise the importance of including liver health and involving people living with liver diseases, in the development and planning of policies.
Brought to you by the Healthy Livers, Healthy Lives Coalition.
